NEW YORK, Sept. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. announced today that it will conduct a conference call to discuss a strategic alliance surrounding one of its Phase II portfolio products for a territory outside the US.
The call will take place today, Wednesday, September 26, 2007, at 8:30am EDT. Michael S. Weiss, Chairman and CEO of Keryx Biopharmaceuticals will host the call.
Interested parties may participate in the call by dialing 1-877-719-9796 (U.S.), 1-719-325-4777 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx’s lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX- 0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965
Keryx Biopharmaceuticals, Inc.
CONTACT: Lauren Fischer, Director - Investor Relations, KeryxBiopharmaceuticals, Inc., +1-212-531-5965
Web site: http://www.keryx.com//
